ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases. Its key marketed products include NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and DAYBUE (trofinetide) for Rett syndrome and other rare neurological disorders.

In Q2 2025, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported revenues of $264.6 million, up 9% year-over-year, driven by 7% growth in NUPLAZID sales and 14% growth in DAYBUE sales. The company completed enrollment in its Phase 3 COMPASS study for ACP-101 targeting Prader-Willi Syndrome, with top-line results expected in early Q4 2025, potentially addressing critical unmet needs in rare genetic disorders.

The business showcased its robust pipeline at its inaugural R&D Day, highlighting nine programs, including seven in Phase 2 or Phase 3 and five expected clinical readouts through 2027. For investors looking into cheap biotech stocks to buy, the company also secured two key patent litigation victories, extending NUPLAZID’s market exclusivity with patents valid through 2030 and 2038.

International expansion for DAYBUE is underway, with named patient supply initiated in Europe, Israel, and select other countries. Recent executive hires, including a Senior VP of Rare Disease Franchise and a Chief Information and Data Officer, reflect a focus on leveraging leadership, data, and digital technologies to drive growth.

Positive market response and strategic execution have been reflected in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s stock, which reached a 52-week high of $25.90 in August 2025, supported by favorable analyst sentiment and multiple price target upgrades.

While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.